MX2021010988A - Derivados de insulina sensibles a la glucosa. - Google Patents

Derivados de insulina sensibles a la glucosa.

Info

Publication number
MX2021010988A
MX2021010988A MX2021010988A MX2021010988A MX2021010988A MX 2021010988 A MX2021010988 A MX 2021010988A MX 2021010988 A MX2021010988 A MX 2021010988A MX 2021010988 A MX2021010988 A MX 2021010988A MX 2021010988 A MX2021010988 A MX 2021010988A
Authority
MX
Mexico
Prior art keywords
insulin derivatives
glucose sensitive
glucose
sensitive insulin
diabetes
Prior art date
Application number
MX2021010988A
Other languages
English (en)
Inventor
Ulrich Sensfuss
Jane Spetzler
Thomas Kruse
Per Sauerberg
Carsten Behrens
Claudia Ulrich Hjørringgaard
Henning Thøgersen
Thomas Hoeg-Jensen
Emiliano Cló
Martin Werner Borchsenius Münzel
Vojtech Balsánek
Zuzana Drobnáková
Ladislav Droz
Miroslav Havránek
Vladislav Kotek
Milan Stengl
Ivan Snajdr
Hana Vánová
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2021010988A publication Critical patent/MX2021010988A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La presente invención se refiere a nuevos derivados de insulina y su uso en el tratamiento o la prevención de afecciones médicas relacionadas con la diabetes. Los derivados de insulina son sensibles a la glucosa y presentan unión a la albúmina sensible a la glucosa. La invención también se refiere a nuevos productos intermediarios. Por último, la invención proporciona una composición farmacéutica que comprende los derivados de insulina de la invención y el uso de la composición en el tratamiento o la prevención de afecciones médicas relacionadas con la diabetes.
MX2021010988A 2019-03-29 2020-03-27 Derivados de insulina sensibles a la glucosa. MX2021010988A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166131 2019-03-29
EP19174671 2019-05-15
PCT/EP2020/058641 WO2020201041A2 (en) 2019-03-29 2020-03-27 Glucose sensitive insulin derivatives

Publications (1)

Publication Number Publication Date
MX2021010988A true MX2021010988A (es) 2021-10-01

Family

ID=70189906

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010988A MX2021010988A (es) 2019-03-29 2020-03-27 Derivados de insulina sensibles a la glucosa.

Country Status (16)

Country Link
US (1) US20220184184A1 (es)
EP (1) EP3946363A2 (es)
JP (2) JP2022527732A (es)
KR (1) KR102507156B1 (es)
CN (1) CN113646329A (es)
AU (1) AU2020255195A1 (es)
BR (1) BR112021016782A2 (es)
CA (1) CA3131832A1 (es)
CL (1) CL2021002397A1 (es)
CO (1) CO2021013251A2 (es)
IL (1) IL285664A (es)
MX (1) MX2021010988A (es)
PE (1) PE20220380A1 (es)
SG (1) SG11202108958PA (es)
TW (2) TW202112397A (es)
WO (1) WO2020201041A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003426A4 (en) * 2019-07-31 2023-07-05 Thermalin Inc. INSULIN ANALOGUES WITH GLUCOSE-REGULATED CONFORMATION SWITCH
PE20230457A1 (es) * 2020-03-31 2023-03-10 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales
EP4247429A1 (en) * 2020-11-19 2023-09-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU628674B2 (en) * 1989-10-19 1992-09-17 Nippon Oil And Fats Company, Limited Polymer complexes of a sugar response type
JP2005526009A (ja) * 2001-12-02 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ 新規グルコース依存性インスリン
EP2254905B1 (en) 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2448962B1 (en) 2009-06-30 2016-10-19 Novo Nordisk A/S Insulin derivatives
WO2014093696A2 (en) 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
EP3291828A4 (en) * 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins
JP2018531900A (ja) 2015-08-25 2018-11-01 ノヴォ ノルディスク アー／エス 新規インスリン誘導体及びその医学的使用
ES2956032T3 (es) * 2017-11-09 2023-12-12 Novo Nordisk As Derivados de unión a albúmina sensibles a la glucosa
KR20210005630A (ko) * 2018-04-16 2021-01-14 유니버시티 오브 유타 리서치 파운데이션 글루코스-반응성 인슐린

Also Published As

Publication number Publication date
KR102507156B1 (ko) 2023-03-09
US20220184184A1 (en) 2022-06-16
SG11202108958PA (en) 2021-09-29
BR112021016782A2 (pt) 2021-11-30
KR20210148143A (ko) 2021-12-07
JP2022527732A (ja) 2022-06-06
WO2020201041A3 (en) 2020-11-19
TW202112397A (zh) 2021-04-01
WO2020201041A2 (en) 2020-10-08
CO2021013251A2 (es) 2022-01-17
EP3946363A2 (en) 2022-02-09
TWI717245B (zh) 2021-01-21
IL285664A (en) 2021-10-31
CA3131832A1 (en) 2020-10-08
TW202102253A (zh) 2021-01-16
CL2021002397A1 (es) 2022-04-22
AU2020255195A1 (en) 2021-10-14
CN113646329A (zh) 2021-11-12
JP2020164525A (ja) 2020-10-08
JP6795718B2 (ja) 2020-12-02
PE20220380A1 (es) 2022-03-18

Similar Documents

Publication Publication Date Title
MX2021010988A (es) Derivados de insulina sensibles a la glucosa.
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
NO20084919L (no) Oksadiazolidindionforbindelse
MX2018005387A (es) Variantes de fgf21.
WO2008043033A3 (en) Fibrillation-resistant insulin and insulin analogues
MA49339A (fr) Conjugués insuline-fc à extension oligomère
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
PH12019502655A1 (en) Acylated insulin compound
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
WO2018169282A3 (ko) Atpif1을 함유하는 당뇨 치료용 약학조성물
EA202190744A1 (ru) Слитый белок glp1-fc и его конъюгат
MX2023000398A (es) Analogos de insulina novedosos y usos de estos.
MX2022014309A (es) Compuestos de insulina acilada de accion temporal prolongada.
WO2020109620A3 (en) Bacterial strains for medical uses
JOP20170040B1 (ar) مركب لخفض جلوكوز الدم
NO20070174L (no) Preparater og fremgangsmater for forebyggelse og kontroll av insulindindusert hypoglykemi
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
Hitman Fasting, Ramadan and diabetes.
WO2020018058A3 (en) The injectable micronized human insulin
WO2023285686A3 (en) Recombinant variants of r-spondin proteins and their use
MX2019005572A (es) Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica.
Badillo et al. PT056 Factors Associated With Uncontrolled Blood Pressure in Primary Care